Mara Goldstein
Stock Analyst at Mizuho
(2.56)
# 2,195
Out of 5,124 analysts
69
Total ratings
48.08%
Success rate
14.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $10.39 | +188.74% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.73 | +266.30% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $7.72 | +3.63% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $23.83 | +76.25% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $15.31 | +226.58% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $21.01 | +114.18% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $98.77 | -22.04% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $3.72 | +88.17% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $0.98 | +714.17% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $42.28 | +112.87% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $7.70 | -54.55% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.34 | +15,284.62% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $6.58 | +203.95% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $105.26 | +23.50% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.26 | -53.05% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.99 | +503.02% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $63.54 | -68.52% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $9.22 | +420.61% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.16 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.83 | +140.14% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $10.39
Upside: +188.74%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.73
Upside: +266.30%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $7.72
Upside: +3.63%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $23.83
Upside: +76.25%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $15.31
Upside: +226.58%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $21.01
Upside: +114.18%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $98.77
Upside: -22.04%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $3.72
Upside: +88.17%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $0.98
Upside: +714.17%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $42.28
Upside: +112.87%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $7.70
Upside: -54.55%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.34
Upside: +15,284.62%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $6.58
Upside: +203.95%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $105.26
Upside: +23.50%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.26
Upside: -53.05%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.99
Upside: +503.02%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $63.54
Upside: -68.52%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $9.22
Upside: +420.61%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $27.16
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.83
Upside: +140.14%